BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed KPTIQ catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:dea92532b0a8560075ad@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:KPTIQ P2 readout (est.): Selinexor (KPT-330) in Patients With Relap
 sed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
DESCRIPTION:Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffus
 e Large B-Cell Lymphoma (DLBCL)\nNCT02227251 | PHASE2 | ACTIVE_NOT_RECRUIT
 ING | sponsor: Karyopharm Therapeutics Inc\nPrimary completion date (ESTIM
 ATED)\; top-line results usually follow later.\nDate precision: month (sho
 wn on the first day)\nTicker KPTIQ (confidence 0.9)\nSource: https://clini
 caltrials.gov/study/NCT02227251\nScheduling/reference data from public rec
 ords\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT02227251
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:18a7b528d038f3bff003@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:KPTIQ P2/P3 readout (est.): A Study of Rituximab-Gemcitabine-Dexame
 thasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relaps
 ed/Refractory Diffuse Large B-cell Lymphoma
DESCRIPTION:A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP)
  With or Without Selinexor in Patients With Relapsed/Refractory Diffuse La
 rge B-cell Lymphoma\nNCT04442022 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING |
  sponsor: Karyopharm Therapeutics Inc\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nDate precision: month (shown on
  the first day)\nTicker KPTIQ (confidence 0.9)\nSource: https://clinicaltr
 ials.gov/study/NCT04442022\nScheduling/reference data from public records\
 ; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT04442022
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d81a19c02672ac630166@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260423
DTEND;VALUE=DATE:20260424
SUMMARY:KPTIQ APPROVAL: XPOVIO
DESCRIPTION:Approved 2026-04-23: XPOVIO (NDA212306 SUPPL18)\nConfidence: co
 nfirmed\nTicker KPTIQ (confidence 0.6)\nSource: https://www.accessdata.fda
 .gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212306\nSche
 duling/reference data from public records\; dates can move. Not investment
 \, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=212306
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
